White House Eyes Up to 250% Drug Tariffs In Bid To Reclaim US Pharma Supply Chain

Big pharma, meet big tariffs.

White House trade adviser Peter Navarro said Thursday the Trump administration may impose tariffs on pharmaceutical imports under a "Section 232" trade investigation, citing national security risks from U.S. dependence on foreign suppliers.

In a CNBC interview, Navarro gave no timeline for the probe but said President Donald Trump's recent executive order to strengthen supply chains would set minimum prices for U.S. drug ingredient makers through long-term contracts, ensuring steady demand. He added that tariffs would help prevent cheap imports from India and China from flooding the market.

Also Read: Trump Administration Opens Probe Into Foreign Drug Imports, Eyes Tariffs Under National Security Law

Earlier this month, Trump floated the possibility of tariffs on imported pharmaceuticals as high as 250%, the steepest rate he has proposed, starting with a "small tariff," rising to 150%, and eventually to 250% within 12 to 18 months. The move is ...